17 completed, 17 terminated, 5 unknown, 1 active not recruiting. 41 Phase 1, 18 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 41 | Completed 17, Terminated 17, Unknown 5, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 18 | Completed 9, Terminated 5, Unknown 3, Recruiting 1 |
Follow B-Cell Chronic Lymphocytic Leukemia: new trials by email Literature Review of B-Cell Chronic Lymphocytic Leukemia trials Research Report on B-Cell Chronic Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias Autologous HuCD19 ( Anti-CD19)CAR T cells, Cyclophosphamide, Fludarabine - Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 132 | 2024-09-03 | 2026-10-16 |
| Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies Anti-CD19 and anti-CD20 bicistronic CAR T- cells, Cyclophosphamide, Fludarabine - Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 58 | 2023-08-28 | 2026-10-16 |
| CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies 0.75x10^6 cells/kg CAR20.19.22 cells, 1x10^6 cells/kg CAR20.19.22 cells, 2.5x10^6 cells/kg CAR20.19.22 cells - B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Medical College of Wisconsin | 4 | 2022-06-30 | 2024-09-19 |
| Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL PBCAR20A, Fludarabine, Cyclophosphamide - Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse | Phase 1 / Phase 2 | Completed | Precision BioSciences, Inc. | 18 | 2020-03-24 | 2023-01-31 |
| T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells, Cyclophosphamide, Fludarabine - Lymphoma, B-Cell, Lymphoma, Non-hodgkins | Phase 1 | Terminated | National Cancer Institute (NCI) | 2 | 2019-12-20 | 2022-02-15 |
| A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies Cirmtuzumab (2-16 kg/mg) plus Ibrutinib, Cirmtuzumab (300mg) plus Ibrutinib, Cirmtuzumab (600 mg) plus ibrutinib - B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Completed | Oncternal Therapeutics, Inc | 95 | 2018-01-03 | 2025-02-12 |
| A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies YY-20394 - B-cell Lymphoma Recurrent, B-cell Chronic Lymphocytic Leukemia | Phase 1 | Unknown | Shanghai YingLi Pharmaceutical Co. Ltd. | 42 | 2017-12-25 | 2018-12-10 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 anti-CD19/20-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Completed | Chinese PLA General Hospital | 100 | 2017-04-01 | 2020-09-02 |
| Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma anti-CD19 CAR-T, Fludarabine, Cyclophosphamide - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia | Phase 1 | Unknown | First Affiliated Hospital of Wenzhou Medical University | 20 | 2016-10-01 | 2019-11-27 |
| Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma anti-CD19 CAR-T, Fludarabine, Cyclophosphamide - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine | 20 | 2016-02-01 | 2017-03-16 |
| A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities Chlorambucil, Obinutuzumab, Placebo - B-Cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Hoffmann-La Roche | 38 | 2015-06-26 | 2021-04-08 |
| Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy Ibrutinib, Erythromycin, Voriconazole - B-Cell Chronic Lymphocytic Leukemia | Phase 1 | Completed | Janssen Research & Development, LLC | 26 | 2015-05-19 | 2017-06-26 |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors ASN002 Dose Escalation, ASN002 RD - Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell | Phase 1 / Phase 2 | Terminated | Asana BioSciences | 51 | 2015-05-01 | 2023-06-07 |
| CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride, rituximab - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Wake Forest University Health Sciences | 1 | 2014-12-01 | 2018-07-02 |
| Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies T-cell therapy + Rituximab + IL-2 - B-Cell Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Unknown | National University Hospital, Singapore | 18 | 2014-12-01 | 2016-06-22 |
| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas lenalidomide, etoposide, prednisone - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | University of Chicago | 55 | 2014-07-29 | 2026-03-11 |
| Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide B-CLL Vaccine, Lenalidomide - B-cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Baylor College of Medicine | 2 | 2013-02-01 | 2016-02-08 |
| Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy anti-CD20-CAR vector-transduced autologous T cells, genetically engineered lymphocyte therapy - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 50 | 2013-01-01 | 2015-09-29 |
| Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL) PCI-32765 - B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Completed | Pharmacyclics LLC. | 33 | 2011-02-01 | 2014-07-24 |
| Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia alemtuzumab, rituximab, PGG beta-glucan - B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Mayo Clinic | 22 | 2011-01-01 | 2020-06-23 |
Showing 20 of 41. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (41) · Lymphoma, Mantle-Cell (13) · Lymphoma, Follicular (12) · Lymphoma, Large B-Cell, Diffuse (11) · Lymphoma, B-Cell, Marginal Zone (9) · Waldenstrom Macroglobulinemia (9) · Leukemia, Prolymphocytic (7) · Lymphoma, B-Cell (7) · Lymphoma, Non-Hodgkin (7) · Hematologic Neoplasms (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Burkitt Lymphoma (4) · Intraocular Lymphoma (4) · Leukemia, Hairy Cell (4) · Hodgkin Disease (3)
Chronic Disease (41) · Disease Attributes (41) · Hematologic Diseases (41) · Hemic and Lymphatic Diseases (41) · Immune System Diseases (41) · Immunoproliferative Disorders (41) · Lymphatic Diseases (41) · Lymphoproliferative Disorders (41) · Neoplasms by Histologic Type (41) · Pathologic Processes (41) · Pathological Conditions, Signs and Symptoms (41) · Neoplasms (40) · Leukemia, Lymphoid (39) · Leukemia (38) · Leukemia, B-Cell (38)
Rituximab (9) · Cyclophosphamide (8) · fludarabine (6) · ibrutinib (5) · alvocidib (3) · fludarabine phosphate (3) · Etoposide (2) · Flow Cytometry (2) · Interleukin-2 (2) · Lenalidomide (2) · Pharmacogenomic Testing (2) · Polymerase Chain Reaction (2) · 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (1) · 6-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine (1) · Alemtuzumab (1)
National Cancer Institute (NCI) (12) · Pharmacyclics LLC. (3) · Chinese PLA General Hospital (2) · AbbVie (prior sponsor, Abbott) (1) · Alexion Pharmaceuticals, Inc. (1) · Asana BioSciences (1) · Baylor College of Medicine (1) · Biogen (1) · First Affiliated Hospital of Wenzhou Medical University (1) · Fred Hutchinson Cancer Center (1) · Genitope Corporation (1) · Hoffmann-La Roche (1) · Janssen Research & Development, LLC (1) · Mayo Clinic (1) · Medical College of Wisconsin (1)
United States (30) · China (5) · Spain (3) · United Kingdom (2) · Argentina (1) · Canada (1) · Israel (1) · Italy (1) · Latvia (1) · Russia (1) · Singapore (1)
James N Kochenderfer, M.D. (3) · John Byrd (2) · Ajay Gopal (1) · Alan List, MD (1) · Brian Till (1) · Chris Storgard, MD (1) · Danelle James, M.D., M.A.S (1) · Gary Gordon, MD (1) · Hanying Bao, PhD (1) · Jeffrey Jones (1) · Jennifer Brown (1) · Jennifer Woyach, MD (1) · Kang Yu, M.D. (1)
PMID 23886836, PMID 26182309, PMID 26813675, PMID 34515338, PMID 15016963, PMID 18616528, PMID 18794884, PMID 19826119, PMID 20626398, PMID 21072184, PMID 22289993, PMID 22308288, PMID 23782158, PMID 24332241, PMID 24352795, PMID 24450857, PMID 24450858, PMID 24615776, PMID 24615777, PMID 24990615, PMID 25317870, PMID 25381051, PMID 25444722, PMID 25724156, PMID 25755291, PMID 25933833, PMID 26116658, PMID 27118540, PMID 29263894, PMID 29437592, PMID 29470582, PMID 31076448, PMID 31196847, PMID 31443741, PMID 31815579, PMID 32209572, PMID 34398557, PMID 34425850, PMID 34935483, PMID 40720747, PMID 41804087, PMID 42827116
U01CA076576 (4), 2014 (2), P30CA016058 (2), 2015 (1), P30CA012197 (1), P30CA014599 (1), P30CA015083 (1), P30CA021765 (1), R21CA112947 (1), R21CA115048 (1), R21CA119519 (1), U01CA062490 (1), U01CA069912 (1)